Hong Kong Stocks Rise 1.46% at Midday, Innovative Drug Sector Leads with Over 6% Gain
0xBroomberg
The Hang Seng Index rose 354 points to 24,695 at Tuesday's midday close, as innovative-drug stocks surged nearly 7% — the national essential-drug list included innovative drugs for the first time, fueling bets on accelerated grassroots adoption.
Why did innovative drugs suddenly lead the market?
The catalyst: China's essential-drug list included innovative drugs for the first time. This means → these drugs can now enter procurement lists at community clinics and township hospitals, not just large urban hospitals.
The Hang Seng Innovative Drug Index jumped 6.97%; the Hang Seng Biotech Index rose 6.13% — the sector outperformed the broader market by a wide margin.
In plain terms = innovative drugs used to sell mainly through big hospitals. Now they have a path into grassroots healthcare, and the market is repricing the addressable market upward.
Which stocks gained the most?
CStone Pharmaceuticals +10.9%, Akeso +9.9%, Innovent Biologics +9.72% — all leading innovative-drug names, directly benefiting from the expanded list.
Alphamab Oncology-B rose over 9%. Its KN026 received another breakthrough-therapy designation — a fast-track regulatory pathway — for first-line HER2-positive breast cancer. This means → the product is one step closer to launch, and regulatory certainty is rising.
LaNova Medicines-B gained over 7%. GIC and LAV both increased stakes on the same day; its AP301 has entered the final sprint toward a new-drug application.
Joinn Laboratories surged over 21%. The company guided first-half net profit growth of up to 1,377%, driven by lab-monkey prices soaring to RMB 200,000 per animal. In plain terms = drug trials require monkeys, supply is tight, prices are surging — and Joinn, as a key supplier, profits directly.
Why did AI stocks rally in tandem?
DeepSeek is in talks with new investors to launch a fresh funding round — the news lifted sentiment across the AI sector.
MINIMAX-W jumped over 13%; Zhipu gained over 7% — both are core large-language-model plays.
Insilico Medicine rose another 11% after announcing a strategic alliance with Bora Pharmaceuticals, with potential total deal value exceeding $2.5 billion. This reflects real capital flowing into the AI-plus-pharma intersection.
Tencent gained over 3%, having officially launched its Hunyuan Hy3 large model earlier this month.
What else stood out — memory chips and other movers?
Overnight, SK Hynix's ADR surged over 27% in the US, pulling Hong Kong's CSOP 2x Leveraged SK Hynix ETF up over 24% — a clear cross-market linkage in the memory-chip space.
China Tourism Group Duty Free rose over 5%, reporting first-half net profit growth of 19.49% year-on-year.
Deepexi gained over 13% after signing an investment-attraction deal with Yueyang Lingang Hi-Tech Zone; Botai Connectivity rose over 9%, continuing its push into the optical-communications supply chain.
What happened on the losing side?
China National Building Material fell over 10%, guiding a first-half swing to a loss of roughly RMB 890 million, mainly due to higher goodwill-impairment provisions. In plain terms = assets acquired earlier have lost value on the books, forcing a one-time write-down that wiped out profits.
This reflects a persistent rule: even in a broadly rising market, a single fundamental blow-up gets priced in fast.
Whether innovative-drug policy tailwinds can translate into actual earnings will be the key test for sector divergence in the second half.
Content is for reference only, not financial advice.